Macdonald R L, Kelly K M
Department of Neurology, University of Michigan Medical Center, Ann Arbor, USA.
Epilepsia. 1995;36 Suppl 2:S2-12. doi: 10.1111/j.1528-1157.1995.tb05996.x.
Established antiepileptic drugs (AEDs) decrease membrane excitability by interacting with neurotransmitter receptors or ion channels. AEDs developed before 1980 appear to act on sodium channels, gamma-aminobutyric acid type A (GABAA) receptors, or calcium channels. Benzodiazepines and barbiturates enhance GABAA receptor-mediated inhibition. Phenytoin (PHT), carbamazepine (CBZ), and possibly valproate (VPA) decrease high-frequency repetitive firing of action potentials by enhancing sodium-channel inactivation. Ethosuximide (ESM) and VPA reduce a low threshold (T-type) calcium-channel current. The mechanisms of action of the new AEDs are not fully established. Gabapentin (GBP) binds to a high-affinity site on neuronal membranes in a restricted regional distribution of the central nervous system. This binding site may be related to a possible active transport process of GBP into neurons; however, this has not been proven, and the mechanism of action of GBP remains uncertain. Lamotrigine (LTG) decreases sustained high-frequency repetitive firing of voltage-dependent sodium action potentials that may result in a preferential decreased release of presynaptic glutamate. The mechanism of action of oxcarbazepine (OCBZ) is not known; however, its similarity in structure and clinical efficacy to CBZ suggests that its mechanism of action may involve inhibition of sustained high-frequency repetitive firing of voltage-dependent sodium action potentials. Vigabatrin (VGB) irreversibly inhibits GABA transaminase, the enzyme that degrades GABA, thereby producing greater available pools of presynaptic GABA for release in central synapses. Increased activity of GABA at postsynaptic receptors may underline the clinical efficacy of VGB.
已有的抗癫痫药物(AEDs)通过与神经递质受体或离子通道相互作用来降低膜兴奋性。1980年以前研发的AEDs似乎作用于钠通道、γ-氨基丁酸A型(GABAA)受体或钙通道。苯二氮䓬类和巴比妥类药物增强GABAA受体介导的抑制作用。苯妥英(PHT)、卡马西平(CBZ)以及可能的丙戊酸盐(VPA)通过增强钠通道失活来减少动作电位的高频重复发放。乙琥胺(ESM)和VPA降低低阈值(T型)钙通道电流。新型AEDs的作用机制尚未完全明确。加巴喷丁(GBP)在中枢神经系统的有限区域分布中与神经元膜上的高亲和力位点结合。该结合位点可能与GBP进入神经元的潜在主动转运过程有关;然而,这尚未得到证实,GBP的作用机制仍不确定。拉莫三嗪(LTG)减少电压依赖性钠动作电位的持续高频重复发放,这可能导致突触前谷氨酸释放优先减少。奥卡西平(OCBZ)的作用机制尚不清楚;然而,其在结构和临床疗效上与CBZ相似,表明其作用机制可能涉及抑制电压依赖性钠动作电位的持续高频重复发放。vigabatrin(VGB)不可逆地抑制γ-氨基丁酸转氨酶,该酶可降解γ-氨基丁酸,从而产生更多可用于在中枢突触释放的突触前γ-氨基丁酸池。γ-氨基丁酸在突触后受体处活性增加可能是VGB临床疗效的基础。